Myriad Expands Stock Repurchase Program | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics today said that its board of directors has authorized the repurchase of an additional $100 million of the firm's outstanding common stock.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.